Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Schizophrenia

  Free Subscription


Articles published in Am J Psychiatry

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    October 2019
  1. KARLSGODT KH
    Using Advanced Diffusion Metrics to Probe White Matter Microstructure in Individuals at Clinical High Risk for Psychosis.
    Am J Psychiatry. 2019;176:777-779.
    PubMed     Text format    


  2. KALIN NH
    Gaining Ground on Schizophrenia: Conceptualizing How to Use Neuroimaging and Genomics in Its Diagnosis and Treatment.
    Am J Psychiatry. 2019;176:771-773.
    PubMed     Text format    


  3. GUR RE, Gur RC
    Functional MRI Predicting Intervention Outcome in Early Psychosis.
    Am J Psychiatry. 2019;176:780-782.
    PubMed     Text format    


  4. BINDER EB
    Polygenic Risk Scores in Schizophrenia: Ready for the Real World?
    Am J Psychiatry. 2019;176:783-784.
    PubMed     Text format    


  5. LIEBERMAN JA, Small SA, Girgis RR
    Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality.
    Am J Psychiatry. 2019;176:794-810.
    PubMed     Text format     Abstract available


  6. KAHN RS
    On the Specificity of Continuous Cognitive Decline in Schizophrenia.
    Am J Psychiatry. 2019;176:774-776.
    PubMed     Text format    


    September 2019
  7. DUGRE JR, Bitar N, Dumais A, Potvin S, et al
    Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind.
    Am J Psychiatry. 2019 Sep 6:appiajp201919030247.
    PubMed     Text format     Abstract available


  8. ALLSWEDE DM, Addington J, Bearden CE, Cadenhead KS, et al
    Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.
    Am J Psychiatry. 2019 Sep 6:appiajp201918111290.
    PubMed     Text format     Abstract available


  9. APPELBAUM PS
    In Search of a New Paradigm for Research on Violence and Schizophrenia.
    Am J Psychiatry. 2019;176:677-679.
    PubMed     Text format    


  10. TANDON R, Shariff SM
    Substance-Induced Psychotic Disorders and Schizophrenia: Pathophysiological Insights and Clinical Implications.
    Am J Psychiatry. 2019;176:683-684.
    PubMed     Text format    


    August 2019
  11. ZHEUTLIN AB, Dennis J, Karlsson Linner R, Moscati A, et al
    Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care Systems.
    Am J Psychiatry. 2019 Aug 16:appiajp201918091085.
    PubMed     Text format     Abstract available


    July 2019
  12. KOCHUNOV P, Huang J, Chen S, Li Y, et al
    White Matter in Schizophrenia Treatment Resistance.
    Am J Psychiatry. 2019 Jul 29:appiajp201918101212.
    PubMed     Text format     Abstract available


  13. ESCOTT-PRICE V, Pardinas AF, Santiago E, Walters J, et al
    The Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank: Response to Lawn et al.
    Am J Psychiatry. 2019;176:574-575.
    PubMed     Text format    


  14. CAO H, Cannon TD
    Cerebellar Dysfunction and Schizophrenia: From "Cognitive Dysmetria" to a Potential Therapeutic Target.
    Am J Psychiatry. 2019;176:498-500.
    PubMed     Text format    


  15. BULLMORE E
    Cortical Thickness and Connectivity in Schizophrenia.
    Am J Psychiatry. 2019;176:505-506.
    PubMed     Text format    


  16. LAWN RB, Sallis HM, Taylor AE, Wootton RE, et al
    Comment on the Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank.
    Am J Psychiatry. 2019;176:573-574.
    PubMed     Text format    


  17. SMUCNY J, Lesh TA, Carter CS
    Baseline Frontoparietal Task-Related BOLD Activity as a Predictor of Improvement in Clinical Symptoms at 1-Year Follow-Up in Recent-Onset Psychosis.
    Am J Psychiatry. 2019 Jul 1:appiajp201918101126.
    PubMed     Text format     Abstract available


  18. ZANELLI J, Mollon J, Sandin S, Morgan C, et al
    Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode.
    Am J Psychiatry. 2019 Jul 1:appiajp201918091088.
    PubMed     Text format     Abstract available


    June 2019
  19. TANG Y, Pasternak O, Kubicki M, Rathi Y, et al
    Altered Cellular White Matter But Not Extracellular Free Water on Diffusion MRI in Individuals at Clinical High Risk for Psychosis.
    Am J Psychiatry. 2019 Jun 24:appiajp201918091044.
    PubMed     Text format     Abstract available


  20. LIZANO P, Lutz O, Ling G, Lee AM, et al
    Association of Choroid Plexus Enlargement With Cognitive, Inflammatory, and Structural Phenotypes Across the Psychosis Spectrum.
    Am J Psychiatry. 2019 Jun 5:appiajp201918070825.
    PubMed     Text format     Abstract available


  21. WANNAN CMJ, Cropley VL, Chakravarty MM, Bousman C, et al
    Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia.
    Am J Psychiatry. 2019 Jun 5:appiajp201918040380.
    PubMed     Text format     Abstract available


    May 2019
  22. NUCIFORA LG, MacDonald ML, Lee BJ, Peters ME, et al
    Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.
    Am J Psychiatry. 2019 May 6:appiajp201918070864.
    PubMed     Text format     Abstract available


  23. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.
    Am J Psychiatry. 2019 May 6:appiajp201918101217.
    PubMed     Text format     Abstract available


    April 2019
  24. BUCHANAN A, Sint K, Swanson J, Rosenheck R, et al
    Correlates of Future Violence in People Being Treated for Schizophrenia.
    Am J Psychiatry. 2019 Apr 24:appiajp201918080909.
    PubMed     Text format     Abstract available


  25. VINOGRADOV S
    Has the Time Come for Cognitive Remediation in Schizophrenia...Again?
    Am J Psychiatry. 2019;176:262-264.
    PubMed     Text format    


    March 2019
  26. BEST MW, Milanovic M, Iftene F, Bowie CR, et al
    A Randomized Controlled Trial of Executive Functioning Training Compared With Perceptual Training for Schizophrenia Spectrum Disorders: Effects on Neurophysiology, Neurocognition, and Functioning.
    Am J Psychiatry. 2019 Mar 8:appiajp201818070849.
    PubMed     Text format     Abstract available


  27. MARTIN WF, Correll CU, Weiden PJ, Jiang Y, et al
    Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Am J Psychiatry. 2019 Mar 8:appiajp201818030280.
    PubMed     Text format     Abstract available


    January 2019
  28. BRADY RO JR, Gonsalvez I, Lee I, Ongur D, et al
    Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia.
    Am J Psychiatry. 2019 Jan 30:appiajp201818040429.
    PubMed     Text format     Abstract available


  29. JALBRZIKOWSKI M, Murty VP, Tervo-Clemmens B, Foran W, et al
    Age-Associated Deviations of Amygdala Functional Connectivity in Youths With Psychosis Spectrum Disorders: Relevance to Psychotic Symptoms.
    Am J Psychiatry. 2019 Jan 18:appiajp201818040443.
    PubMed     Text format     Abstract available


  30. ESCOTT-PRICE V, Pardinas AF, Santiago E, Walters J, et al
    The Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank.
    Am J Psychiatry. 2019 Jan 4:appiajp201818020140.
    PubMed     Text format     Abstract available


  31. WEINBERGER DR
    Polygenic Risk Scores in Clinical Schizophrenia Research.
    Am J Psychiatry. 2019;176:3-4.
    PubMed     Text format    


  32. WEINBERGER DR
    Thinking About Schizophrenia in an Era of Genomic Medicine.
    Am J Psychiatry. 2019;176:12-20.
    PubMed     Text format     Abstract available


    December 2018
  33. GHOSH A, Noble D
    The Influence of Unmeasured Confounding Effects in a Study of Antipsychotic Discontinuation in First-Episode Schizophrenia.
    Am J Psychiatry. 2018;175:1266-1267.
    PubMed     Text format    


    November 2018
  34. RIGLIN L, Hammerton G, Heron J, Collishaw S, et al
    Developmental Contributions of Schizophrenia Risk Alleles and Childhood Peer Victimization to Early-Onset Mental Health Trajectories.
    Am J Psychiatry. 2018 Nov 29:appiajp201818010075.
    PubMed     Text format     Abstract available


  35. BERGEN SE, Ploner A, Howrigan D, O'Donovan MC, et al
    Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia.
    Am J Psychiatry. 2018 Nov 5:appiajp201817040467.
    PubMed     Text format     Abstract available


  36. ZHANG JP, Robinson D, Yu J, Gallego J, et al
    Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.
    Am J Psychiatry. 2018 Nov 5:appiajp201817121363.
    PubMed     Text format     Abstract available


    October 2018
  37. MARTINEZ A, Gaspar PA, Hillyard SA, Andersen SK, et al
    Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications.
    Am J Psychiatry. 2018 Oct 3:appiajp201818010072.
    PubMed     Text format     Abstract available


  38. DI PRINZIO P, Morgan VA, Bjork J, Croft M, et al
    Intellectual Disability and Psychotic Disorders in Children: Association With Maternal Severe Mental Illness and Exposure to Obstetric Complications in a Whole-Population Cohort.
    Am J Psychiatry. 2018 Oct 3:appiajp201817101153.
    PubMed     Text format     Abstract available


    September 2018
  39. ZHANG T, Li H, Tang Y, Niznikiewicz MA, et al
    Validating the Predictive Accuracy of the NAPLS-2 Psychosis Risk Calculator in a Clinical High-Risk Sample From the SHARP (Shanghai At Risk for Psychosis) Program.
    Am J Psychiatry. 2018;175:906-908.
    PubMed     Text format    


    August 2018
  40. XIAO Y, Sun H, Shi S, Jiang D, et al
    White Matter Abnormalities in Never-Treated Patients With Long-Term Schizophrenia.
    Am J Psychiatry. 2018 Aug 2:appiajp201817121402.
    PubMed     Text format     Abstract available


  41. VERMEULEN JM, Schirmbeck F, Blankers M, van Tricht M, et al
    Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study.
    Am J Psychiatry. 2018 Aug 2:appiajp201818010069.
    PubMed     Text format     Abstract available


  42. KAHN RS
    On the Continued Benefit of Antipsychotics After the First Episode of Schizophrenia.
    Am J Psychiatry. 2018;175:712-713.
    PubMed     Text format    


    July 2018
  43. KRIVINKO JM, Erickson SL, Ding Y, Sun Z, et al
    Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease.
    Am J Psychiatry. 2018 Jul 19:appiajp201817080858.
    PubMed     Text format     Abstract available


  44. ROBERTSON AG, Easter MM, Lin H, Frisman LK, et al
    Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes.
    Am J Psychiatry. 2018;175:665-673.
    PubMed     Text format     Abstract available


    June 2018
  45. EL-MALLAKH RS, Furdek C
    Cycloid Psychosis.
    Am J Psychiatry. 2018;175:502-505.
    PubMed     Text format    


    May 2018
  46. NELSON JC, Bickford D, Delucchi K, Fiedorowicz JG, et al
    Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2018 May 24:appiajp201817101138.
    PubMed     Text format     Abstract available


  47. FARRELL M, Lichtenstein M, Crowley JJ, Filmyer DM, et al
    Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington's Disease.
    Am J Psychiatry. 2018;175:400-407.
    PubMed     Text format    


  48. ROSENHECK R
    Toward Dissemination of Secondary Prevention for Psychosis.
    Am J Psychiatry. 2018;175:393-394.
    PubMed     Text format    


    April 2018
  49. TIIHONEN J, Tanskanen A, Taipale H
    20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Am J Psychiatry. 2018 Apr 6:appiajp201817091001.
    PubMed     Text format     Abstract available


  50. JEZEQUEL J, Lepleux M, Kahn RS, Honnorat J, et al
    Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:382-383.
    PubMed     Text format    


  51. GHOSE S
    Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis?
    Am J Psychiatry. 2018;175:303-304.
    PubMed     Text format    


  52. DAMIANI S, Fusar-Poli L
    The Cats of Louis Wain: A Thousand Ways to Draw One's Mind.
    Am J Psychiatry. 2018;175:315.
    PubMed     Text format    


    March 2018
  53. ANDERSON KK, Norman R, MacDougall A, Edwards J, et al
    Effectiveness of Early Psychosis Intervention: Comparison of Service Users and Nonusers in Population-Based Health Administrative Data.
    Am J Psychiatry. 2018 Mar 2:appiajp201717050480.
    PubMed     Text format     Abstract available


  54. KAUPPI K, Rosenthal SB, Lo MT, Sanyal N, et al
    Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
    Am J Psychiatry. 2018 Mar 2:appiajp201717040410.
    PubMed     Text format     Abstract available


  55. NOORDSY DL, Burgess JD, Hardy KV, Yudofsky LM, et al
    Therapeutic Potential of Physical Exercise in Early Psychosis.
    Am J Psychiatry. 2018;175:209-214.
    PubMed     Text format    


    February 2018
  56. PAYNE JL
    The Psychoses of Menstruation and Childbearingby Ian Brockington, M.D., F.R.C.P. Cambridge, England, Cambridge University Press, 2017, 391 pp., $140.00 (hardcover).
    Am J Psychiatry. 2018;175:190-191.
    PubMed     Text format    


  57. GOFF DC
    Optimizing the Pharmacologic Treatment of Individuals With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:101-102.
    PubMed     Text format    


  58. ROBINSON DG, Schooler NR, Correll CU, John M, et al
    Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.
    Am J Psychiatry. 2018;175:169-179.
    PubMed     Text format     Abstract available


    December 2017
  59. MCGUIRE P, Robson P, Cubala WJ, Vasile D, et al
    Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
    Am J Psychiatry. 2017 Dec 15:appiajp201717030325.
    PubMed     Text format     Abstract available


  60. HAMILTON HK, Williams TJ, Ventura J, Jasperse LJ, et al
    Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia.
    Am J Psychiatry. 2017 Dec 5:appiajp201716111203.
    PubMed     Text format     Abstract available


    November 2017
  61. LIVNY A, Reichenberg A, Fruchter E, Yoffe R, et al
    A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201716121384.
    PubMed     Text format     Abstract available


  62. STARZER MSK, Nordentoft M, Hjorthoj C
    Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201717020223.
    PubMed     Text format     Abstract available


  63. GOES FS, Sawa A
    Psychosis Beyond the 22q11.2 Deletion: Do Additional Genetic Factors Play a Role?
    Am J Psychiatry. 2017;174:1027-1029.
    PubMed     Text format    


  64. SCHOOLER NR
    Long-Term Outcomes of Psychosis: Naturalistic Follow-Up After Initial Hospitalization.
    Am J Psychiatry. 2017;174:1030-1031.
    PubMed     Text format    


  65. KOTOV R, Fochtmann L, Li K, Tanenberg-Karant M, et al
    Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.
    Am J Psychiatry. 2017;174:1064-1074.
    PubMed     Text format     Abstract available


  66. VELTHORST E, Fett AJ, Reichenberg A, Perlman G, et al
    The 20-Year Longitudinal Trajectories of Social Functioning in Individuals With Psychotic Disorders.
    Am J Psychiatry. 2017;174:1075-1085.
    PubMed     Text format     Abstract available


    October 2017
  67. KANE JM
    Clozapine Reduces All-Cause Mortality.
    Am J Psychiatry. 2017;174:920-921.
    PubMed     Text format    


  68. RAHMAN T, Ash DM, Lauriello J, Rawlani R, et al
    Misleading Guidance From Pharmacogenomic Testing.
    Am J Psychiatry. 2017;174:922-924.
    PubMed     Text format    


    September 2017
  69. LEVITT JJ, Nestor PG, Levin L, Pelavin P, et al
    Reduced Structural Connectivity in Frontostriatal White Matter Tracts in the Associative Loop in Schizophrenia.
    Am J Psychiatry. 2017 Sep 15:appiajp201716091046.
    PubMed     Text format     Abstract available


    August 2017
  70. SANDOVAL LR, Torous J, Keshavan MS
    Smartphones for Smarter Care? Self-Management in Schizophrenia.
    Am J Psychiatry. 2017;174:725-728.
    PubMed     Text format    


    July 2017
  71. DAVIDSON M, Saoud J, Staner C, Noel N, et al
    Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201717010122.
    PubMed     Text format     Abstract available


  72. BASSETT AS, Lowther C, Merico D, Costain G, et al
    Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2017 Jul 28:appiajp201716121417.
    PubMed     Text format     Abstract available


  73. WIMBERLEY T, MacCabe JH, Laursen TM, Sorensen HJ, et al
    Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201716091097.
    PubMed     Text format     Abstract available


  74. ANDREASSEN OA
    Diabetes and Schizophrenia-New Findings for an Old Puzzle.
    Am J Psychiatry. 2017;174:616-617.
    PubMed     Text format    


  75. PHILIP NS, Nelson BG, Frohlich F, Lim KO, et al
    Low-Intensity Transcranial Current Stimulation in Psychiatry.
    Am J Psychiatry. 2017;174:628-639.
    PubMed     Text format     Abstract available


  76. SHARMA A, Wolf DH, Ciric R, Kable JW, et al
    Common Dimensional Reward Deficits Across Mood and Psychotic Disorders: A Connectome-Wide Association Study.
    Am J Psychiatry. 2017;174:657-666.
    PubMed     Text format     Abstract available


    June 2017
  77. COYLE JT
    Cortical Pyramidal Neurons Show a Selective Loss of New Synapses in Chronic Schizophrenia.
    Am J Psychiatry. 2017;174:510-511.
    PubMed     Text format    


    May 2017
  78. LEUCHT S, Leucht C, Huhn M, Chaimani A, et al
    Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Am J Psychiatry. 2017 May 25:appiajp201716121358.
    PubMed     Text format     Abstract available


  79. GOFF DC, Falkai P, Fleischhacker WW, Girgis RR, et al
    The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.
    Am J Psychiatry. 2017 May 5:appiajp201716091016.
    PubMed     Text format     Abstract available


  80. HORVITZ-LENNON M, Mattke S, Predmore Z, Howes OD, et al
    The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.
    Am J Psychiatry. 2017;174:421-426.
    PubMed     Text format    


  81. NAKIMULI-MPUNGU E
    Our Most Troubling Madness: Case Studies in Schizophrenia Across Culturesedited by T.M. Luhrmann and Jocelyn Marrow. Oakland, University of California Press, 2016, 304 pp., $29.95 (paperback).
    Am J Psychiatry. 2017;174:490.
    PubMed     Text format    


  82. HAUSER RA, Factor SA, Marder SR, Knesevich MA, et al
    KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Am J Psychiatry. 2017;174:476-484.
    PubMed     Text format     Abstract available


  83. BOU KHALIL R
    On the Magical Thinking Related to Mental Health in Chad.
    Am J Psychiatry. 2017;174:427-428.
    PubMed     Text format    


    April 2017
  84. ROSENHECK RA, Estroff SE, Sint K, Lin H, et al
    Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis.
    Am J Psychiatry. 2017 Apr 21:appiajp201716111273.
    PubMed     Text format     Abstract available


  85. LAVRETSKY H
    Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
    Am J Psychiatry. 2017;174:307-308.
    PubMed     Text format    


    March 2017
  86. MACDONALD ML, Alhassan J, Newman JT, Richard M, et al
    Selective Loss of Smaller Spines in Schizophrenia.
    Am J Psychiatry. 2017 Mar 31:appiajp201716070814.
    PubMed     Text format     Abstract available


  87. PATERSON C, Wang Y, Hyde TM, Weinberger DR, et al
    Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.
    Am J Psychiatry. 2017;174:256-265.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: